Evidence map›Paper›PMID 36614279›Full record

ArticleInternational journal of molecular sciences2023

The Double-Edged Sword of Oleuropein in Ovarian Cancer Cells: From Antioxidant Functions to Cytotoxic Effects.

Stefania Scicchitano, Eleonora Vecchio, Anna Martina Battaglia, Manuela Oliverio, Monica Nardi, Antonio Procopio, Francesco Costanzo, Flavia Biamonte, Maria Concetta Faniello

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. In Vitro Protective Effects of a Standardized Extract ofAntioxidants (Basel, Switzerland) · 2024
    Article
  14. Review
  15. The Role of Natural Products in Immunopharmacology.International journal of molecular sciences · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Stefania ScicchitanoResearch Center of Biochemistry and Advanced Molecular Biology, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-3566-7214
Eleonora VecchioResearch Center of Biochemistry and Advanced Molecular Biology, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0001-8422-2679
Anna Martina BattagliaResearch Center of Biochemistry and Advanced Molecular Biology, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
Manuela OliverioDepartment of Health Science, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-1918-5813
Monica NardiDepartment of Health Science, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0001-6617-9320
Antonio ProcopioDepartment of Health Science, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
Francesco CostanzoResearch Center of Biochemistry and Advanced Molecular Biology, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
Flavia BiamonteResearch Center of Biochemistry and Advanced Molecular Biology, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
Maria Concetta FanielloResearch Center of Biochemistry and Advanced Molecular Biology, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
Magna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oleuropein plays a key role as a pro-oxidant as well as an antioxidant in cancer. In this study, the activity of oleuropein, in an in vitro model of ovarian (OCCs) and breast cancer cells (BCCs) was investigated. Cell viability and cell death were analyzed. Oxidative stress was measured by CM-H2DCFDA flow cytometry assay. Mitochondrial dysfunction was evaluated based on mitochondrial reactive oxygen species (ROS) and GPX4 protein levels. Further, the effects on iron metabolism were analyzed by measuring the intracellular labile iron pool (LIP). We confirmed that high doses of oleuropein show anti-proliferative and pro-apoptotic activity on HEY and MCF-7 cells. Moreover, our results indicate that low doses of oleuropein impair cell viability without affecting the mortality of cells, and also decrease the LIP and ROS levels, keeping them unchanged in MCF-7 cells. For the first time, our data show that low doses of oleuropein reduce erastin-mediated cell death. Interestingly, oleuropein decreases the levels of intracellular ROS and LIP in OCCs treated with erastin. Noteworthily, we observed an increased amount of ROS scavenging enzyme GPX4 together with a consistent reduction in mitochondrial ROS, confirming a reduction in oxidative stress in this model.

Indexed as

AntioxidantsOvarian NeoplasmsFemaleHumansIridoid GlucosidesIridoidsIronReactive Oxygen SpeciesAntioxidantsIridoid GlucosidesIridoidsIronoleuropeinReactive Oxygen Speciesoleuropeinovarian cancerROS

Identifiers

PMID36614279
PMCPMC9821453
OpenAlexW4313583836

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.